Aktis Oncology (NASDAQ:AKTS) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• Aktis Oncology has a consensus “Moderate Buy” rating from eight analysts, including six buys, one strong buy and one sell. The average 12-month price target is $34.60, with targets including $40 from Raymond James and $33 from JPMorgan.
• Shares opened at $22.65, down 0.8%, giving the company a market capitalization of about $1.21 billion. The stock has traded between $14.72 and $34.19 over the past year.
• The company reported quarterly revenue of $3.23 million, exceeding estimates of $2.23 million, but its loss of $0.38 per share narrowly missed expectations. A director also sold 4,856 shares for approximately $119,263, while insiders own 3.30% of the company.

Aktis Oncology (NASDAQ:AKTS - Get Free Report) has been given a consensus rating of "Moderate Buy" by the eight research firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $34.60.

Several analysts have recently commented on the stock. Raymond James Financial began coverage on shares of Aktis Oncology in a research report on Monday, June 15th. They issued a "strong-buy" rating and a $40.00 price target on the stock. Weiss Ratings raised Aktis Oncology from a "sell (d)" rating to a "sell (d+)" rating in a research report on Tuesday, June 23rd. Wall Street Zen downgraded Aktis Oncology from a "hold" rating to a "sell" rating in a research report on Saturday, July 25th. JPMorgan Chase & Co. upped their target price on shares of Aktis Oncology from $30.00 to $33.00 and gave the company an "overweight" rating in a report on Tuesday, July 14th. Finally, William Blair started coverage on shares of Aktis Oncology in a research note on Wednesday, April 29th. They set an "outperform" rating on the stock.

Insider Buying and Selling

In other news, Director Ken Herrmann sold 4,856 shares of the stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $24.56, for a total transaction of $119,263.36. Following the transaction, the director directly owned 3,506 shares in the company, valued at $86,107.36. This represents a 58.07% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 3.30% of the stock is owned by company insiders.

Aktis Oncology Trading Down 0.8%

Shares of AKTS stock opened at $22.65 on Thursday. The stock has a 50 day simple moving average of $24.39 and a 200-day simple moving average of $20.98. The company has a market cap of $1.21 billion and a price-to-earnings ratio of -59.61. Aktis Oncology has a 12-month low of $14.72 and a 12-month high of $34.19.

Aktis Oncology (NASDAQ:AKTS - Get Free Report) last announced its quarterly earnings results on Monday, May 11th. The technology company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.01). The firm had revenue of $3.23 million during the quarter, compared to analyst estimates of $2.23 million. On average, equities analysts forecast that Aktis Oncology will post -1.64 earnings per share for the current fiscal year.

Aktis Oncology Company Profile

Aktis Oncology NASDAQ: AKTS is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company's activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source